Research & Development
Lupin's VISUfarma signs European licensing deal for presbyopia therapy YUVEZZI
20 August 2026 - Indian pharmaceutical companies Lupin Limited (BSE: 500257; NSE: LUPIN) said on Thursday it has agreed an exclusive licensing deal with commercial-stage ophthalmic pharmaceutical comp...
Aqua Medical treats second type 2 diabetes patient in IDE trial of investigational PIMA procedure
19 August 2026 - Aqua Medical Inc, a clinical-stage medical technology company advancing Endoscopic Metabolic Restoration, announced on Tuesday the treatment of the first West Coast patient (second ov...
Harbour BioMed IND for HBM7004 approved by China's NMPA
18 August 2026 - Global biopharmaceutical company Harbour BioMed (HKEX: 02142), which develops antibody therapeutics in immunology and oncology, said on Tuesday that China's National Medical Prod...
Hansa Biopharma reports first Australian transplant using Idefirix
18 August 2026 - Swedish immunomodulatory therapy company Hansa Biopharma AB (STO: HNSA) on Tuesday announced that the first commercial patient in Australia has received a living donor kidney transpla...
Lupin's Pitolisant Tablets receives US FDA approval
18 August 2026 - India-based global pharmaceutical company Lupin Limited (BSE: 500257; NSE: LUPIN; REUTERS: LUPIN.BO; BLOOMBERG: LPCIN) announced on Monday that it has received the final approval from...
Acurx receives FDA conditional acceptance for ibezapolstat brand name
17 August 2026 - Biopharmaceutical company Acurx Pharmaceuticals Inc (NASDAQ: ACXP) disclosed on Monday that it has received conditional FDA acceptance for CIFBEZY, the proposed proprietary name for i...